Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07150481
Starting soon Phase 2/3

Intraoperative Lidocaine Infusion

NCT07150481 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Phase 2/3
Started
2025-10
Last updated
2025-09-02

Condition(s) studied

Enhanced Recovery After Anesthesia

Investigational drug(s) / intervention(s)

IV Lidocaine infusion →IV normal saline

IV Lidocaine infusion: 2 mg/kg/h (the total dose of lidocaine per hour will be calculated and add to normal saline 0.9% to total volume 50 ml and infused by a rate 50 ml/h till the end of the procedure

IV normal saline: IV normal saline 0.9% , rate 50 ml/h

Study summary

This study aims to evaluate the analgesic and anti-inflammatory effect of perioperative intravenous lidocaine infusion and in turn the return of gastric motility in patients undergoing elective laparoscopic cholecystectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 18 - 60 years 2. Elective laparoscopic cholecystectomy for symptomatic cholelithiasis or chronic cholecystitis 3. ASA physical status I-II 4. BMI \< 35 kg/m2 5. Preoperative CRP \<20 mg/L 6. Informed consent provided Exclusion Criteria: 1. Acute cholecystitis or biliary pancreatitis 2. Conversion to open surgery 3. Pre-op CRP \>20 mg/L 4. Allergy to lidocaine or local anesthetics 5. Known hepatic or renal dysfunction 6. Chronic inflammatory conditions 7. Current immunosuppressive therapy 8. Cardiac arrhythmias or heart block without pacemaker 9. ASA physical status III, IV or above 10. Pregnancy or breastfeeding 11. Psychiatric disorders

Primary outcome measure(s)

  • Postoperative CRP level — postoperative day 1 (24 hours postoperative)
    measurement of Postoperative CRP level

Trial sites (1)

FacilityCityRegionStatus
Assiut university main hospital Asyut Assiut Governorate, Egypt,

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Outcomes of Different Techniques of Aortoostial Coronary Intervention Assessed by Coronary Computed Tomography Angiography Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07150481 on ClinicalTrials.gov ↗ ← All trials in Egypt